Drug Profile
Research programme: protein-protein interaction modulators - SYGNIS Pharma AG
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator SYGNIS Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Unspecified
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Germany
- 15 Jan 2013 SYGNIS Pharma's protein-protein interaction screening technology is available for licensing in Europe and the USA as of 15 Jan 2013. http://www.sygnis.de/
- 15 Jan 2013 Early research in undefined indication in Germany (unspecified route)